MIRA INFORM REPORT

 

 

Report Date :

15.10.2012

 

IDENTIFICATION DETAILS

 

Name :

ARKRAY GLOBAL BUSINESS INC

 

 

Registered Office :

Arkray Global Business KK (Overseas trading division of Arkray Inc)

 

 

Country :

Japan

 

 

Financials (as on) :

31.10.2008

 

 

Date of Incorporation :

July 2001

 

 

Com. Reg. No.:

1300-01-023753 (Kyoto-Nakagyoku)

 

 

Legal Form :

Limited Company

 

 

Line of Business :

Manufacturer, export of diabetes-related clinical equipment & supplies

 

 

No. of Employees :

326 employees

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 


 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

japan - ECONOMIC OVERVIEW

 

In the years following World War II, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (1% of GDP) helped Japan develop a technologically advanced economy. Two notable characteristics of the post-war economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features are now eroding under the dual pressures of global competition and domestic demographic change. Japan's industrial sector is heavily dependent on imported raw materials and fuels. A tiny agricultural sector is highly subsidized and protected, with crop yields among the highest in the world. Usually self-sufficient in rice, Japan imports about 60% of its food on a caloric basis. Japan maintains one of the world's largest fishing fleets and accounts for nearly 15% of the global catch. For three decades, overall real economic growth had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the after effects of inefficient investment and an asset price bubble in the late 1980s that required a protracted period of time for firms to reduce excess debt, capital, and labor. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, Japan in 2011 stood as the fourth-largest economy in the world after second-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2011. A sharp downturn in business investment and global demand for Japan's exports in late 2008 pushed Japan further into recession. Government stimulus spending helped the economy recover in late 2009 and 2010, but the economy contracted again in 2011 as the massive 9.0 magnitude earthquake in March disrupted manufacturing. Electricity supplies remain tight because Japan has temporarily shut down almost all of its nuclear power plants after the Fukushima Daiichi nuclear reactors were crippled by the earthquake and resulting tsunami. Estimates of the direct costs of the damage - rebuilding homes, factories, and infrastructure - range from $235 billion to $310 billion, and GDP declined almost 0.5% in 2011. Prime Minister Yoshihiko NODA has proposed opening the agricultural and services sectors to greater foreign competition and boosting exports through membership in the US-led Trans-Pacific Partnership trade talks and by pursuing free-trade agreements with the EU and others, but debate continues on restructuring the economy and reining in Japan's huge government debt, which exceeds 200% of GDP. Persistent deflation, reliance on exports to drive growth, and an aging and shrinking population are other major long-term challenges for the economy.

 

Source : CIA

 

 

 


Company name

 

ARKRAY GLOBAL BUSINESS INC

 

REGD NAME

 

Arkray Global Business KK (Overseas trading division of Arkray Inc)

 

 

MAIN OFFICE

 

Kyoto Miyuki Bldg 10F, 689 Karasumadori Shijo-Noboru Nakagyoku Kyoto 604-8153 JAPAN

Tel: 050-5527-9306     Fax: 075-662-8973

 

*.. The is its Laboratory at: 57 Nishi-Aketacho Higashi Kujo Minamiku Kyoto 601-8045, as given

 

URL:                 http://www.arkray.co.jp

E-Mail address:            info@arkray.co.jp

 

ACTIVITIES

 

Mfg, export of diabetes-related clinical equipment & supplies

 

 

BRANCHES

 

Nationwide (Tot 23)

 

 

OVERSEAS

 

Europe, Australia, USA, China & Korea (--Sales Offices)

 

 

FACTORIES

 

Shiga (2)

(Overseas): China, USA


OFFICERS

 

SHIGEKI YAMADA, PRES

Kosuke Nakanishi, dir

Takeshi Matsuda, dir

 

Yen Amount:     In million Yen, unless otherwise stated

 

 

SUMMARY    

 

FINANCES        FAIR                             A/SALES          Yen 37,420 M*

PAYMENTS      No Complaints          CAPITAL           Yen 99 M*

TREND STEADY                       WORTH            Yen 30,904 M*

STARTED         1963                             EMPLOYES      326

 

*.. All figures are of the parent, Arkray Inc as of Oct/2007 fiscal term, as the subject does not release financials as they are consolidated by the parent.

 

 

COMMENT

 

EXPORTER OF DIABETES-RELATED CLINICAL EQUIPMENT, WHOLLY oWNED BY ARKRAY INC.

 

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

 

 

HIGHLIGHTS

           

The subject company was established on the overseas trading division separated from Arkray Inc, mfg of diabetes-related clinical instruments, at the caption address.  This is an overseas trading division of the parent with management and staff members fully integrated with the parent, Arkray Inc.  Specializes in exporting the goods of the parent to over 80 countries worldwide.  Sales offices are in Europe, USA, Australia, China and Korea.

 

(Affiliates):

Domestic: Arkray Marketing Inc (Domestic marketing division);

Arkray Global Business Inc (International marketing division);

Arkray Infinity Inc, Arkray Factory Inc (--Mfg divisions);

Arkray Digital Laboratory Inc (PC software development);

Arkray Optron Inc (Mfg of optical goods)

Overseas: Arkray Global Inc Seoul Sales Office;

Arkray Europe BV; Arkray America Inc; Color Trading Spz;

Arkray Marketing Shanghai Inc,

Arkray Factory USA Inc; Arkray Factory Shanghai Inc (--Mfg)

 

 

FINANCIAL INFORMATION

           

Financials are not disclosed as they are consolidated by the parent, Arkray Inc, which financials are only partially disclosed.  Financials are only disclosed until Oct/2007 fiscal term and not ever since.

 

The sales volume for Oct/2007 fiscal term amounted to Yen 37420 million, a 33% down from Yen 54,300 million in the previous term.  The net profit was posted at Yen 782 million, compared with Yen 160 million a year ago.

 

The financial situation is considered FAIR and good for ORDINARY business engagements. 

 

 

REGISTRATION

 

Date Registered:  Jul 2001

Regd No.:         1300-01-023753 (Kyoto-Nakagyoku)

Legal Status:      Limited Company (Kabushiki Kaisha)

Authorized:         800 shares

Issued:              200 shares

Sum:                   Yen 10 million

Major shareholders (%): Arkray Inc*(100)

 

*.. Mfr of diabetes-related clinical testing equipment, at the caption address, founded 1963, capital Yen 99 million, sales Yen 37,420 million, net profit Yen 782 million, employees 200,

pres Takeshi Masuda;

Financials as attached (See SUPPLEMENTS).

 

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

 

Activities: Exports diabetes-related clinical equipment & supplies, reagents, functional foods

as overseas trading division of Arkray Inc to over 80 countries worldwide (--100%).

 

(Handling items):

Automatic Glycohemoglobin Analyzer, Fully Automated Urine Analyzer, Versatile Urine Analysis System, Compact Urine Analyzer, Urine test strips, Dry Clinical Chemistry Analyzer, Automated analyzer for clinical chemistry, Electrolyte Analyzer with Ion-Selective Electrodes, Blood Ammonia Meter, Blood glucose test meter, Lancet device for blood collection, Osmotic Pressure, Simplified Blood Lactate Test Meter,

 

(Principal overseas clients):

Bayer Corporation (USA); A Menarini Diagnostic (Italy); Tamro Corporation (Finland); Axon Lab AG (Switz); Heska Corporation (USA); IRIS (USA), Bayer Corp, A Menarini, Tamro Corp, other

 

Clients: [Hospitals, laboratories, medical institutions] Exports to USA, Germany, Italy, Korea, China, other.

No. of accounts: Unavailable

Domestic areas of activities: Nationwide

 

Suppliers: [Mfr] Supplied wholly from the parent, Arkray Inc.

 

Payment record: No Complaints

 

Location: Business area in Kyoto.  Office premises at the caption address are owned and maintained satisfactorily.

 

Bank References:

Bank of Kyoto (Inari)

MUFG (Kyoto-Chuo)

Relations: Satisfactory

 

 

FINANCES

(In Million Yen)

 

Consolidated Financials of the parent, Arkray Inc.

 

 

31/10/2008

31/10/2007

31/10/2006

31/10/2005

Annual Sales

 

38,000

37,420

55,530

5,400

Recur. Profit

 

 

1,663

 

 

Net Profit

 

800

782

260

222

Total Assets

 

 

N/A

N/A

N/A

Net Worth

 

 

36,800

36,018

35,758

Capital, Paid-Up

 

 

99

99

99

Div.P.Share(¥)

 

 

0.00

0.00

0.00

<Analytical Data>

(%)

(%)

(%)

(%)

    S.Growth Rate

1.55

-32.61

928.33

-89.43

    Current Ratio

 

 

..

..

..

    N.Worth Ratio

 

..

..

..

    N.Profit/Sales

2.11

2.09

0.47

4.11

 

Note: Financials are only partially disclosed.  No financials are disclosed since Oct.2008 fiscal term

Forecast (or estimated) for the 31/10/2008 fiscal term.

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.52.70

UK Pound

1

Rs.84.51

Euro

1

Rs.68.16

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.